It was shown that CD38 knockdown or treatment with CD38 inhibitors increases the NAD+ levels and ameliorates mitochondrial dysfunction and glucose intolerance in mice, leading to therapeutic interventions against Alzheimer’s disease, diabetes, and tumors [155,156,157,158]. The gene discussed is CD38; the disease is early-onset autosomal dominant Alzheimer disease.